Lipocine Overview
- Year Founded
-
1997
- Status
-
Public
- Employees
-
17
- Stock Symbol
-
LPCN
- Investments
-
1
- Share Price
-
$4.73
- (As of Tuesday Closing)
Lipocine General Information
Description
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.
Contact Information
Website
www.lipocine.comCorporate Office
- 675 Arapeen Drive
- Suite 202
- Salt Lake City, UT 84108
- United States
Corporate Office
- 675 Arapeen Drive
- Suite 202
- Salt Lake City, UT 84108
- United States
Lipocine Stock Performance
As of 03-Dec-2024, Lipocine’s stock price is $4.73. Its current market cap is $25.3M with 5.35M shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.73 | $4.30 | $2.40 - $11.79 | $25.3M | 5.35M | 31.9K | -$0.75 |
Lipocine Financials Summary
As of 30-Sep-2024, Lipocine has a trailing 12-month revenue of $7.92M.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 1,463 | (9,017) | 954 | 51,978 |
| Revenue | 7,923 | (2,851) | 500 | 16,141 |
| EBITDA | (5,234) | (17,689) | (11,294) | (498) |
| Net Income | (4,056) | (16,352) | (10,759) | (634) |
| Total Assets | 20,698 | 23,001 | 37,543 | 52,482 |
| Total Debt | 0 | 0 | 230 | 2,311 |
Lipocine Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Lipocine Comparisons
Industry
Financing
Details
Lipocine Competitors (37)
One of Lipocine’s 37 competitors is Marinus Pharmaceuticals, a Formerly VC-backed company based in Radnor, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Marinus Pharmaceuticals | Formerly VC-backed | Radnor, PA | ||||
| Acerus Pharmaceuticals | Corporation | Mississauga, Canada | ||||
| Synlogic | Formerly VC-backed | Cambridge, MA | ||||
| InMed Pharmaceuticals | Corporation | Vancouver, Canada | ||||
| Agile Therapeutics | Formerly VC-backed | Princeton, NJ |
Lipocine Patents
Lipocine Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-12156881-B2 | Oral (17-β)-3-oxoandrost-4-en-17-yl tridecanoate therapy | Active | 09-Feb-2024 | ||
| US-11969434-B1 | Oral allopregnanolone compositions and methods of use | Active | 29-Aug-2022 | ||
| US-20240173335-A1 | Oral allopregnanolone compositions and methods of use | Pending | 29-Aug-2022 | ||
| US-20240252513-A1 | Oral allopregnanolone compositions and methods of use | Pending | 29-Aug-2022 | ||
| US-20230390304-A1 | Method and composition for treating epilepsy | Pending | 02-Jun-2022 | A61K31/57 |
Lipocine Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Lipocine Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Lipocine Acquisitions (1)
Lipocine’s most recent deal was a Merger/Acquisition with Marathon Bar. The deal was made on 24-Jul-2013.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Marathon Bar | 24-Jul-2013 | Merger/Acquisition | Food Products |
Lipocine ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Lipocine FAQs
-
When was Lipocine founded?
Lipocine was founded in 1997.
-
Where is Lipocine headquartered?
Lipocine is headquartered in Salt Lake City, UT.
-
What is the size of Lipocine?
Lipocine has 17 total employees.
-
What industry is Lipocine in?
Lipocine’s primary industry is Drug Delivery.
-
Is Lipocine a private or public company?
Lipocine is a Public company.
-
What is Lipocine’s stock symbol?
The ticker symbol for Lipocine is LPCN.
-
What is the current stock price of Lipocine?
As of 03-Dec-2024 the stock price of Lipocine is $4.73.
-
What is the current market cap of Lipocine?
The current market capitalization of Lipocine is $25.3M.
-
What is Lipocine’s current revenue?
The trailing twelve month revenue for Lipocine is $7.92M.
-
Who are Lipocine’s competitors?
Marinus Pharmaceuticals, Acerus Pharmaceuticals, Synlogic, InMed Pharmaceuticals, and Agile Therapeutics are some of the 37 competitors of Lipocine.
-
What is Lipocine’s annual earnings per share (EPS)?
Lipocine’s EPS for 12 months was -$0.75.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
